3-(呋喃-2-基)-1,2-恶唑 | 651059-65-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(呋喃-2-基)-1,2-恶唑
• 英文名称: 3-(2-furyl)isoxazole
• 英文别名: Isoxazole, 3-(2-furanyl)-；3-(furan-2-yl)-1,2-oxazole
• CAS: 651059-65-3
• 化学式: C₇H₅NO₂
• 分子量: 135.122
• InChiKey: CSWYVAJJSBNRHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-cyclopropyl-5-phenylpenta-1,4-diyn-3-ol 、 3-(呋喃-2-基)-1,2-恶唑 在 1,3-双(2,6-二-异丙基苯基)咪唑-2-亚基金(I)氯化物 、 silver trifluoromethanesulfonate 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 4.0h， 以95%的产率得到(Z)-2-cyclopropyl-1-(1-(furan-2-yl)-3-oxoprop-1-en-1-yl)-5-phenyl-1Hpyrrole-3-carbaldehyde
  参考文献：
  名称：

  Gold-Catalyzed [4 + 1]-Annulation Reactions between 1,4-Diyn-3-ols and Isoxazoles To Construct a Pyrrole Core

  摘要：

  This work reports gold-catalyzed [4 + 1]-annulation reactions between 1,4-diyn-3-ols and isoxazoles or benzisoxazoles to yield pyrrole derivatives. The reaction chemoselectivity is controlled by an initial attack of an isoxazole at a less hindered alkyne to form gold carbenes, further inducing a 1,2-migration of a second alkyne group. A broad substrate scope of 1,4-diyn-3-ols, isoxazoles and even benzisoxazoles highlighted the reaction utility.

  DOI：

  10.1021/acs.orglett.8b01398
• 作为产物：
  描述：

  糠醛肟 在 N-氯代丁二酰亚胺 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 12.66h， 生成 3-(呋喃-2-基)-1,2-恶唑
  参考文献：
  名称：

  由苯基乙烯基硒化物一锅法合成3-取代异恶唑

  摘要：

  采用苯基乙烯基硒化物对腈氧化物进行 1,3-双极环加成反应，随后氧化消除提供 3-取代的异恶唑，在一锅两步转化中具有良好的收率。

  DOI：

  10.1055/s-2003-44354

文献信息

• Polymer-Supported Vinyl Sulfone as an Efficient Reagent for the Synthesis of 3-Monosubstituted Isoxazoles
  作者：Guo-Jian Wu、Shou-Ri Sheng、Dan Li、Li-Fan Xu、Zhen-Zhong Huang

  DOI：10.1080/00397911.2012.762718

  日期：2013.11.17

  Abstract Polystyrene-supported vinyl sulfone reagent has been developed and used for solid-phase organic synthesis of 3-monosubstituted isoxazoles by 1,3-dipolar cycloaddition reaction with nitrile oxides and subsequent cleavage from the polymer support through an elimination reaction in the presence of potassium tert-butoxide. The advantages of this method include straightforward operation, good yield

  摘要 聚苯乙烯负载的乙烯基砜试剂已被开发并用于固相有机合成 3-单取代异恶唑，通过与腈氧化物的 1,3-偶极环加成反应，然后在钾存在下通过消除反应从聚合物载体上裂解。叔丁醇。该方法的优点是操作简单、收率好、粗品纯度高。图形概要
• Efficient and Regioselective One-Pot Synthesis of 3-Substituted and 3,5-Disubstituted Isoxazoles
  作者：Shibing Tang、Jinmei He、Yongquan Sun、Liuer He、Xuegong She

  DOI：10.1021/ol901626n

  日期：2009.9.3

  A series of 3-substituted and 3,5-disubstituted isoxazoles have been efficiently synthesized in moderate to excellent yields by the reaction of N-hydroxyl-4-toluenesulfonamide with α,β-unsaturated aldehydes/ketones. This novel strategy is associated with readily available starting materials, mild conditions, high regioselectivity, and wide scope.

  通过N-羟基-4-甲苯磺酰胺与α，β-不饱和醛/酮的反应，已经以中等至优异的产率有效地合成了一系列3-取代的和3，5-二取代的异恶唑。这种新颖的策略与容易获得的起始原料，温和的条件，较高的区域选择性和广泛的范围有关。
• Efficient and Regioselective Synthesis of 5-Hydroxy-2-isoxazolines: Versatile Synthons for Isoxazoles, β-Lactams, and γ-Amino Alcohols
  作者：Shibing Tang、Jinmei He、Yongquan Sun、Liuer He、Xuegong She

  DOI：10.1021/jo1000065

  日期：2010.3.19

  An efficient and highly regioselective protocol was developed for the preparation of 5-hydroxy-2-isoxazolines, which have been proved to be versatile synthons for isoxazles, beta-hydroxy oximes, and gamma-amino alcohols. beta-Lactams, commonly embedded in the skeletons of bioactive natural products, were also synthesized in two steps from beta-hydroxy oximes, providing a new strategy for the synthesis of this kind of compounds.
• US7470722B2
  申请人：——

  公开号：US7470722B2

  公开（公告）日：2008-12-30
• [EN] MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE<br/>[FR] COMPOSES SULFONAMIDE MULTICYCLIQUES INHIBANT L'HISTONE DESACETYLASE POUR LE TRAITEMENT DE MALADIE
  申请人：KALYPSYS INC

  公开号：WO2005123089A2

  公开（公告）日：2005-12-29

  Disclosed herein are carbonyl compounds of Formula (I) as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.